Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Syndax Pharmaceuticals (SNDX) Receivables - Other (2016 - 2025)

Syndax Pharmaceuticals has reported Receivables - Other over the past 11 years, most recently at $28.1 million for Q4 2025.

  • Quarterly results put Receivables - Other at $28.1 million for Q4 2025, up 673.04% from a year ago — trailing twelve months through Dec 2025 was $28.1 million (up 673.04% YoY), and the annual figure for FY2025 was $28.1 million, up 2061.54%.
  • Receivables - Other for Q4 2025 was $28.1 million at Syndax Pharmaceuticals, up from $20.9 million in the prior quarter.
  • Over the last five years, Receivables - Other for SNDX hit a ceiling of $28.1 million in Q4 2025 and a floor of $158000.0 in Q1 2022.
  • Median Receivables - Other over the past 5 years was $1.6 million (2024), compared with a mean of $5.5 million.
  • Biggest five-year swings in Receivables - Other: surged 2925.87% in 2022 and later crashed 95.92% in 2023.
  • Syndax Pharmaceuticals' Receivables - Other stood at $429000.0 in 2021, then surged by 35.9% to $583000.0 in 2022, then soared by 110.46% to $1.2 million in 2023, then surged by 196.25% to $3.6 million in 2024, then soared by 673.04% to $28.1 million in 2025.
  • The last three reported values for Receivables - Other were $28.1 million (Q4 2025), $20.9 million (Q3 2025), and $16.6 million (Q2 2025) per Business Quant data.